Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
NCT02794857 is registered in ClinicalTrials.gov with Neuraltus Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
- Lead sponsor
- Neuraltus Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 29, 2016
- Completion date
- December 12, 2017
- Enrollment
- 138 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.